Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Bone Marrow Transplantation volume 55, pages 633–640 (2020)Cite this article

Subjects

Abstract

Information regarding the curative role of allogeneic stem cell transplantation (allo-HCT) in systemic anaplastic large cell lymphoma (sALCL) is scarce. We analyzed the results of allo-HCT in patients with relapsed/refractory sALCL with special emphasis on the role of brentuximab vedotin (BV) as a bridge to allo-HCT. Forty-four patients (24 females, median age 38 years) with sALCL were included. Twenty-three patients (52%) received BV before allo-HCT; BV-treated patients were more heavily pretreated (≥3 lines of therapy in 74% vs. 38%, p = 0.04). Twenty-three patients (52%) were in complete remission (CR) at allo-HCT. Three-year nonrelapse mortality and incidence of relapse (IR) after allo-HCT were 7% and 40%, respectively. With a median follow-up of 39 (12–69) months for survivors, 3-year progression-free survival (PFS) and overall survival were 53% and 74%, respectively. Univariate analysis showed that heavily pretreated patients and those not in CR had a higher IR and a lower PFS. The use of BV before transplant did not impact on any of the outcomes. Allo-HCT is a curative therapeutic strategy in a significant proportion of patients with relapsed/refractory sALCL; BV does not seem to modify transplant-related outcomes but might be able to render more patients candidates for this curative treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.

    Article  Google Scholar 

  2. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496–504.

    Article  CAS  Google Scholar 

  3. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93:2697–706.

    CAS  PubMed  Google Scholar 

  4. Sibon D, Fournier M, Brière J, Lamant L, Haioun C, Coiffier B, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol. 2012;30:3939–46.

    Article  Google Scholar 

  5. Parilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124:1473–80.

    Article  Google Scholar 

  6. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20:1533–38.

    Article  CAS  Google Scholar 

  7. Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: Results of a prospective multicenter study. J Clin Oncol. 2009;27:106–13.

    Article  CAS  Google Scholar 

  8. d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–99.

    Article  Google Scholar 

  9. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, et al. Graft versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22:2172–6.

    Article  Google Scholar 

  10. Delioukina M, Zain J, Palmer JM, Tsai N, Thomas S, Forman S. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transpl. 2012;47:65–72.

    Article  CAS  Google Scholar 

  11. Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012;26:520–6.

    Article  CAS  Google Scholar 

  12. Zain J, Palmer JM, Delioukina M, Thomas S, Tsai NC, Nademanee A, et al. Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk Lymphoma. 2011;52:1463–73.

    Article  Google Scholar 

  13. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol. 2008;26:2264–71.

    Article  Google Scholar 

  14. Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31:3100–09.

    Article  Google Scholar 

  15. Rohlfing S, Dietrich S, Witzens-Harig M, Hegenbart U, Schönland S, Luft T, et al. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. Ann Hematol. 2018;97:1241–50.

    Article  Google Scholar 

  16. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176:750–8.

    Article  CAS  Google Scholar 

  17. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190–96.

    Article  CAS  Google Scholar 

  18. Illidge T, Bouabdallah R, Chen R, Gopal AK, Moskowitz CH, Ramchandren R, et al. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk lymph. 2015;56:703–10.

    Article  CAS  Google Scholar 

  19. Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic tranmsplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013;98:611–4.

    Article  CAS  Google Scholar 

  20. Mediwake H, Morris K, Curley C, Butler J, Kennedy G. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience. Intern Med J. 2017;47:574–8.

    Article  CAS  Google Scholar 

  21. Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, et al. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. Br J Haematol. 2018;181:86–96.

    Article  CAS  Google Scholar 

  22. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

    Article  Google Scholar 

  23. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.

    CAS  Google Scholar 

  24. Shulman HM, Sullivan KM, Weiden PL. McDonald 325 GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.

    Article  CAS  Google Scholar 

  25. R Core Team. R: a language for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014.

  26. Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M, et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol. 2014;15:757–66.

    Article  CAS  Google Scholar 

  27. Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G, et al. Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. Haematologica. 2017;102:1931–5.

    Article  CAS  Google Scholar 

  28. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130:2709–17.

    Article  CAS  Google Scholar 

  29. Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, et al. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): a phase 1b open-label study. Am J Hematol. 2018;93:607–14.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We acknowledge the kind support of all physicians and data managers of the participating transplant centers.

Author information

Authors and Affiliations

  1. Clinical Hematology Department, Institut Català d’Oncologia—Hospitalet, Barcelona, Spain

    E. Domingo-Domènech & A. Sureda

  2. Lymphoma Working Party, EBMT, Paris, France

    A. Boumendil & H. Finel

  3. Pathology Department, Hospital Universitari de Bellvitge, Barcelona, Spain

    F. Climent

  4. Hematology Department, Hopital St. Louis, Paris, France

    G. Socié

  5. Universitaetklinikum, Dresden, Germany

    F. Kroschinsky

  6. Hope Directorate, St. James’s Hospital, Dublin, Ireland

    E. Vandenbergue

  7. University Hospital Center Rebro, Zagreb, Croatia

    D. Nemet

  8. University of Münster, Muenster, Germany

    M. Stelljes

  9. Department of Internal Medicine, University of Saarland, Homburg, Germany

    J. T. Bittenbring

  10. Department of Hematology and Oncology, University Hospital Bristol, Bristol, UK

    S. Robinson

  11. St. Bartholomew’s Hospital, Barts Health NHS Trust, London, UK

    S. Montoto

  12. Medizinische Klinik u. Poliklinik V, University of Heidelberg, Heidelberg, Germany

    P. Dreger

Authors
  1. E. Domingo-Domènech
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Boumendil
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Climent
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Socié
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Kroschinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Finel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Vandenbergue
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. Nemet
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Stelljes
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J. T. Bittenbring
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S. Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S. Montoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A. Sureda
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. P. Dreger
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Corresponding author

Correspondence to A. Sureda.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Domingo-Domènech, E., Boumendil, A., Climent, F. et al. Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 55, 633–640 (2020). https://doi.org/10.1038/s41409-019-0732-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0732-9

Search

Advanced search

Quick links